AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19667281
Drug: Efavirenz at
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz at 600 mg/day plus stavudine‐lamivudine
Trial: 17561956
Drug: Sustained-release carbamazepine
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release carbamazepine (CBZ)
Trial: 10911490
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg) daily
Trial: 10911490
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg) every 3 days
Trial: 364260
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of acetylsalicylic acid
Trial: 27294812
Drug: 12-step facilitation
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-step facilitation therapy
Trial: 21499123
Drug: Low-Dose IFN‐α-2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Dose IFN‐α-2a treatment
Trial: 16723584
Drug: Brecanavir (BCV)
RxNorm normalized name: Brecanavir
DrugBank: Brecanavir (DB04887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brecanavir (BCV) 300 mg coadministered with 100 mg ritonavir (RTV)
Trial: 16723584
Drug: Brecanavir (BCV)
RxNorm normalized name: Brecanavir
DrugBank: Brecanavir (DB04887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brecanavir (BCV) (doses ranging from 25 mg to 800 mg)
Trial: 6406459
Drug: Bupropion hydrochloride
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion hydrochloride (100, 200, and 400 mg)
Trial: 6406459
Drug: d‐amphetamine sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine sulfate (15 and 30 mg)
Trial: 3873175
Drug: Dexamethasone antenatal
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone antenatal therapy
Trial: 31710096
Drug: School-based interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based interventions (prohibition of sugary snack consumption, teacher supervised daily brushing using fluoridated toothpaste, oral health education)
Trial: 31710096
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control (tooth brushing and oral health education)
Trial: 31710096
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control (only oral health education)
Trial: 30053283
Drug: Canola oil
RxNorm normalized name: Canola Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 39% (P < 0.05) compared to baseline.
Trial: 30053283
Drug: High oleic
RxNorm normalized name: High Oleic Sunflower Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oleic acid-canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 34% (P < 0.05) compared to baseline.
Trial: 30053283
Drug: DHA-enriched high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched high oleic acid-canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 55% (P < 0.05) compared to baseline.
Trial: 30053283
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil and safflower oil blend diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 49% (P < 0.05) compared to baseline.
Trial: 30053283
Drug: Flax oil
RxNorm normalized name: Flax oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flax oil and safflower oil blend diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 51% (P < 0.05) compared to baseline.
Trial: 18641036
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of Triomune 40 (stavudine 40 mg, lamivudine 150 mg, nevirapine 200 mg)
Trial: 18641036
Drug: Branded formulation
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded formulation of Triomune 40 (stavudine 40 mg, lamivudine 150 mg, nevirapine 200 mg)
Trial: 18641036
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of Triomune 40
Trial: 18641036
Drug: Branded formulation
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded formulation of Triomune 40
Trial: 10536549
Drug: morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine plus diclofenac 1 mg kg‐1
Trial: 10536549
Drug: morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine plus paracetamol 15-20 mg kg‐1
Trial: 10536549
Drug: morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine plus a combination of both diclofenac and paracetamol
Trial: 31482947
Drug: Saltier bread
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saltier bread samples (no specific dosage mentioned)
Trial: 31482947
Drug: Bread with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread with oregano seasoning (no specific dosage mentioned)
Trial: 25744418
Drug: Dairy-consumption group
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy-consumption group (400 g/d for 24 wk)
Trial: 19188391
Drug: Doripenem (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doripenem (500 mg every 8 hours)
Trial: 19188391
Drug: Levofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (250 mg every 24 hours)
Trial: 18221624
Drug: Treatment step
RxNorm normalized name: PYRITHIONE ZINC 2.14 mg in 1 mL TOPICAL CREAM [Australian Gold Metro 365 Medicated Leave-In Treatment Step 3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment step 1
Trial: 18221624
Drug: Treatment step
RxNorm normalized name: PYRITHIONE ZINC 2.14 mg in 1 mL TOPICAL CREAM [Australian Gold Metro 365 Medicated Leave-In Treatment Step 3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment step 2
Trial: 18221624
Drug: Treatment step
RxNorm normalized name: PYRITHIONE ZINC 2.14 mg in 1 mL TOPICAL CREAM [Australian Gold Metro 365 Medicated Leave-In Treatment Step 3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment step 3
Trial: 18221624
Drug: Treatment step
RxNorm normalized name: PYRITHIONE ZINC 2.14 mg in 1 mL TOPICAL CREAM [Australian Gold Metro 365 Medicated Leave-In Treatment Step 3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment step 4
Trial: 18221624
Drug: Increasing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing treatment steps
Trial: 9139274
Drug: IL‐6 urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐6 urinary excretion in IDDM patients with albuminuria (mean = 7.43 +/‐ 8.29 pg/mg creatinine)
Trial: 9139274
Drug: TGF‐beta urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF‐beta urinary excretion in IDDM patients with albuminuria (mean = 42.0 +/‐ 30.0 pg/mg creatinine)
Trial: 2409613
Drug: Heparin-DHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-DHE
Trial: 6662638
Drug: Injection in
RxNorm normalized name: Emend Injection Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection in the upper arm
Trial: 6662638
Drug: Subcutaneous thrombin
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous thrombin administration
Trial: 18663487
Drug: Intensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive group training protocol (exercise therapy, back school, operant-conditioning principles)
Trial: 16204716
Drug: SUV(100) normalized
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUV(100) normalized by serum glucose with a g-value of -0.5
Trial: 16204716
Drug: SUV(100) normalized
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUV(100) normalized by serum glucose with a g-value of -0.5 in patients with extreme glucose values
Trial: 10206443
Drug: TVP‐low‐cholesterol diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVP‐low‐cholesterol diet (17 to 30 mg/d)
Trial: 10206443
Drug: Standard cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cholesterol diet (190 to 550 mg/d)
Trial: 7639017
Drug: EcSf2a-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcSf2a-2 vaccine strain, administered as 4 doses of ca. 7 x 10(8) c.f.u. on days 0, 3, 14, and 17
Trial: 7639017
Drug: EcSf2a-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcSf2a-2 vaccine strain
Trial: 25223836
Drug: Selisistat 5-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selisistat 5-600 mg single dose
Trial: 25223836
Drug: Selisistat 100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selisistat 100-300 mg once daily for 7 days
Trial: 21469386
Drug: Control (general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (general therapy without HBO)
Trial: 11223448
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 or 40 mg daily)
Trial: 9364692
Drug: 6-12 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-12 micrograms intradermal (i.d.) inoculation in three or four divided doses (Groups A-F)
Trial: 9364692
Drug: 4 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 micrograms intradermal (i.d.) inoculation in four doses
Trial: 9364692
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group G) received three 10 micrograms intramuscular (i.m.) inoculations
Trial: 7908838
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of sustained-release somatuline
Trial: 7908838
Drug: Injections of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections of sustained-release somatuline at 2-week intervals over a 6-month period
Trial: 27780197
Drug: Dextrose gel
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose gel
Trial: 20721698
Drug: Bivalirudin (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (high-dose and low-dose protocols)
Trial: 20721698
Drug: Heparin (standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (standardized protocol)
Trial: 15011419
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg hyperbaric bupivacaine
Trial: 2007107
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hyperbaric bupivacaine
Trial: 10225782
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment by selective adsorption followed by intravenous IgG
Trial: 8782169
Drug: Selective adsorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective adsorption using a tryptophan-linked polyvinyl alcohol gel adsorbent
Trial: 2825746
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg) inhalation in volunteers and patients
Trial: 2825746
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (1 mg kg‐1) oral administration in healthy volunteers
Trial: 2825746
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (0.2 microgram kg‐1 for 30 min) intravenous administration in healthy volunteers
Trial: 2825746
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg) multiple dosing four times daily for 7 days in volunteers
Trial: 2825746
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg) multiple dosing four times daily for 1, 6, and 12 months in patients
Trial: 29029563
Drug: Single-session, transdiagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session, transdiagnostic preventive intervention based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Trial: 24362411
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with metformin (1000 mg BID) and liraglutide (1.2 mg QD s.c.)
Trial: 24362411
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg QD s.c.)
Trial: 24362411
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg BID)
Trial: 12637459
Drug: Doxorubicin 50
RxNorm normalized name: DOXOrubicin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m² plus docetaxel 75 mg/m² (AT)
Trial: 15611510
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² (AC)
Trial: 8626853
Drug: Daily sc
RxNorm normalized name: Blackhead Eliminating Daily Scrub
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sc GH treatment at a dose of 0.2 or 0.3 IU/kg
Trial: 24220224
Drug: Treadmill training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treadmill training (15 min) plus conventional therapy
Trial: 15699836
Drug: rhIL-10 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-10 (1, 10, or 25 microg/kg) administered 2 mins before lipopolysaccharide (4 ng/kg)
Trial: 15699836
Drug: rhIL-10 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-10 (1, 10, or 25 microg/kg) administered 2 hrs before lipopolysaccharide (4 ng/kg)
Trial: 14664657
Drug: Levofloxacin 750mg
RxNorm normalized name: LEVOFLOXACIN 750MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750mg once daily for 7-14 days
Trial: 14664657
Drug: Levofloxacin 500mg
RxNorm normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500mg once daily for 7-14 days
Trial: 14664657
Drug: Levofloxacin 750mg
RxNorm normalized name: LEVOFLOXACIN 750MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750mg once daily for 5 days
Trial: 14664657
Drug: Levofloxacin 500mg
RxNorm normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500mg once daily for 7 days
Trial: 14664657
Drug: Levofloxacin 500mg
RxNorm normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500mg once daily for 10-14 days
Trial: 14664657
Drug: Levofloxacin 500mg
RxNorm normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500mg once daily for 28 days
Trial: 14664657
Drug: Levofloxacin 500mg
RxNorm normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500mg once daily for 7-10 days
Trial: 24401765
Drug: Prochlorperazine 5
RxNorm normalized name: prochlorperazine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 5 mg
Trial: 11392068
Drug: Placebo (NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl 0.9% 4 mL)
Trial: 8806903
Drug: BAY u
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY u 3405 (50 mg)
Trial: 1634480
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg tablet twice daily
Trial: 4067974
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of oxygen
Trial: 10406187
Drug: AdoMet (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdoMet (1200 mg/day, orally)
Trial: 7756795
Drug: Human surfactant
RxNorm normalized name: recombinant human surfactant protein D
DrugBank: Zelpultide alfa (DB18587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human surfactant therapy
Trial: 2256759
Drug: Chronic daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic daily treatment with octreotide acetate
Trial: 375460
Drug: Levamisole treatment
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole treatment (3 days before operation and 3 days a fortnight thereafter)
Trial: 17584349
Drug: Adherence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence therapy (8 weekly sessions)
Trial: 15101598
Drug: Cemented implant‐supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemented implant‐supported single‐tooth crown
Trial: 15101598
Drug: Screw‐retained implant‐supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screw‐retained implant‐supported single‐tooth crown
Trial: 11434356
Drug: L-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine supplementation (0.1 g/kg body weight/day)
Trial: 9504626
Drug: Previously treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previously treated MM patients on treatment (n = 60)
Trial: 9504626
Drug: Previously treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previously treated MM patients off treatment (n = 45)
Trial: 3288846
Drug: Hormone substitution
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone substitution therapy with 17 beta‐oestradiol
Trial: 12656701
Drug: gonadotropin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gonadotropin‐releasing hormone agonist/estradiol group (n = 9)
Trial: 12656701
Drug: gonadotropin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gonadotropin‐releasing hormone agonist/placebo group (n = 12)
Trial: 1540452
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clonidine and bupivacaine
Trial: 25256937
Drug: 5.2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.2 μg of rhFSH
Trial: 25256937
Drug: 6.9 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.9 μg of rhFSH
Trial: 25256937
Drug: 8.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.6 μg of rhFSH
Trial: 25256937
Drug: 10.3 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.3 μg of rhFSH
Trial: 25256937
Drug: 12.1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.1 μg of rhFSH
Trial: 25256937
Drug: 11 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 μg (150 IU) of follitropin alfa
Trial: 25256937
Drug: rhFSH (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhFSH (various doses)
Trial: 25256937
Drug: rhFSH (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhFSH (highest doses)
Trial: 22733160
Drug: Intermittent androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent androgen deprivation (IAD) therapy with 11.25 mg leuprorelin acetate
Trial: 15722066
Drug: NuvaRing (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuvaRing (15 microg of ethinylestradiol and 120 microg of etonogestrel daily)
Trial: 15722066
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (150 microg of levonorgestrel and 30 microg of ethinylestradiol)
Trial: 10500014
Drug: Psyllium (5.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (5.1 g twice daily)
Trial: 31675992
Drug: Patient-reported data
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-reported data collection prior to randomisation and treatment
Trial: 31675992
Drug: Monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring of participant dropout due to delays in treatment
Trial: 26814240
Drug: HYD coarse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYD coarse particles 60 mg
Trial: 26814240
Drug: HYD fine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYD fine particles 60 mg
Trial: 26814240
Drug: Hydrocodone powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone powder 60 mg
Trial: 25453486
Drug: Guanfacine extended-release
RxNorm normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine extended-release (GXR) 0.05-0.12mg/kg/day (6-12 years: 1-4mg/day; 13-17 years: 1-7mg/day)
Trial: 19843053
Drug: Palosuran 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palosuran 125 mg b.i.d. for 4 weeks